Pharma & Biotech Capital Spending Trends: Navigating a Shift in Global Manufacturing
Executive Summary
The global pharma and biotech sector is in the midst of a sustained capital spending cycle, driven by U.S. reshoring, tari pressures, and the structural shift toward outsourced manufacturing. Drawing on Industrial Info Resources' (IIR) database of 338,000+ operational plants, this white paper examines whether the industry is experiencing a temporary CapEx boom or a permanent realignment of where and how it manufactures.
Please complete the form to receive the exclusive white paper.
Thank you, your form has been submitted!
You will receive an email with a copy of the white paper.
If you would like to view other insights, visit our Industrial Insights Podcast Series page.